Phase 3 N=576 CHAMP: Study of NVK-002 in Children With Myopia
Myopia
Primary: Number of Subjects' Eyes That Show < 0.50 D Myopia Progression (SER, Spherical Equivalent Refraction) at the Month 36 Visit — 79; 106; 61 participants' eyes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=41 A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
Chronic Graft-versus-host-disease
Primary: Phase 1: Number of Participants With DLTs — 0; 0; 0; 2 Participants
N/A N=59,644 Impact of Anesthesiology Interventions on Postoperative Outcomes in Adult Patients Undergoing Shoulder Surgery
Postoperative Complications
Primary: Postoperative Death, Admission, Readmission or Emergency Department Visits — 1,784; 1,132; 85; 98 Participants
N/A N=14 Precision Orthodontics: A Comparison of Custom vs Traditional Bracket Treatment Efficiency
Dental Malocclusion
Primary: Length of Bonding Appointment — 33 minutes
Phase 1 N=30 Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen
Skin Cancer
Primary: DNA Damage Level by Cyclobutane Pyrimidine Dimer (CPD) Measurement — 2.48; 2.18; 2.64; 1.14 Optical Density Units — p=0.003
Phase 2 N=4 M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
Colon Adenocarcinoma · High-Frequency Microsatellite Instability · Metastatic Malignant Solid Neoplasm
Primary: Percentage of Circulating DNA Clearance — 0 percentage of DNA cleared
Phase 2 N=39 Transgender Estradiol Affirming Therapy
Transgenderism
Primary: Total Testosterone Level in Transgender Female Patients — 498.6; 481.3; 505.3; 62.7 pg/mL — p=0.005
Phase 3 N=18 A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder
Major Depressive Disorder
Primary: HAMD-17 — 16.4; 16.2 score on a scale
Phase 3 N=131 Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid
Alzheimer's Disease
Primary: Regional Cerebral Blood Flow Using Arterial Spin-labeling MRI — 55.7; 54.5 mL/g/min — p=0.17
Phase 4 N=14 Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI
Osteonecrosis
Primary: Signal to Noise Ratio (SNR) — 33.82; 129.56 dB — p=0.002
Phase 1 N=27 A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants
Healthy Participants
Primary: Part A: Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 0; 0; 0; 1 Participants
Phase 2 N=39 A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC
Inflammatory Bowel Diseases · Colitis, Ulcerative
Primary: Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score — -6.4 score on a scale
Phase 3 N=94 Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study
Human Immunodeficiency Virus Type 1 (HIV-1)
Primary: Concentrations at the End of the Dosing Interval (Ctau) of CAB LA 400 mg Following Administration CAB LA + RPV LA — 2.759; 2.670; 2.607; 2.632 microgram per milliliter…
Phase 4 N=2 Study for Patients Previously Treated in Avapritinib Clinical Trials
Gastrointestinal Stromal Tumors
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) — 0 Participants
Phase 2 N=44 Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
Locally Advanced Epithelioid Hemangioendothelioma · Metastatic Epithelioid Hemangioendothelioma · Unresectable Epithelioid Hemangioendothelioma
Primary: Objective Response Rate — 9.5 Percentage